Peter DeMuth
Chief Scientific Officer Elicio Therapeutics
Dr. Pete DeMuth is a founding scientist at Elicio and currently serves as Chief Scientific Officer, leading the development of technology platforms for cancer immunotherapeutics from early research to clinical development. To this role, he brings over 15 years of experience in oncology, immunology and materials science.
Prior to joining Elicio, Pete oversaw efforts to develop novel technologies for immunotherapy and vaccine development at the Massachusetts Institute of Technology’s Koch Institute for Integrative Cancer Research in affiliation with the Ragon Institute of Massachusetts General Hospital, MIT, and Harvard University, where he received recognition from the National Institutes of Health and the American Chemical Society.
In 2015, Pete received the Quadrant Award from Quadrant AG, a global manufacturer and innovator in polymer materials science, for research he completed while at the Koch Institute at MIT. Pete has also been an NIH Fellow at the Whitehead Institute for Biomedical Research and a research fellow at Novartis Vaccines and Diagnostics. As a Howard Hughes Research Fellow at the University of Maryland, he was awarded the University Medal for his development of advanced technologies for oncology therapeutics. In 2024, Pete was named in PharmaVoice 100s: Trailblazers and was named in the 40 Under 40 in Cancer.
Seminars
- Leveraging lymph-node-targeted vaccine technology to activate durable anti-tumour immune responses against KRAS-mutant cancers
- Demonstrating clinical progress with KRAS-directed immunotherapy, including prior Phase 1 data and emerging results from a randomized Phase 2 study in pancreatic cancer
- Advancing immunotherapy beyond small-molecule KRAS inhibition to prevent recurrence in high-risk patients following surgery and chemotherapy
